Cell Therapy News/Articles, page-8233

  1. 13,220 Posts.
    lightbulb Created with Sketch. 3625
    Thanks @LeftYahoo and @otherperspective - great posts as usual.

    One question that has been nagging at me.

    "This is a SEISMIC shift to my mind and underlines perhaps a deeper significance of the CHF study that few seen to have perceived: rex-L may ultimately have a greater role as a prophylactic than as a traditional therapeutic." and that can be extended to Rem-L for C19 ARDS too as our sweet spot is no longer the "sickest of the sick" patients...

    A long way to go, but will the industry/ insurers (i.e. Pharmacoeconomic) support such a costly preventative treatment?
    Costs associated with preventative measures have a different value to the actual treatment itself, at least to the patients.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$1.59
Change
-0.025(1.55%)
Mkt cap ! $2.031B
Open High Low Value Volume
$1.61 $1.62 $1.57 $6.345M 3.987M

Buyers (Bids)

No. Vol. Price($)
6 44493 $1.59
 

Sellers (Offers)

Price($) Vol. No.
$1.59 4159 1
View Market Depth
Last trade - 16.10pm 08/07/2025 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.